<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 28 Feb 2021 11:41:35 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>强生新冠疫苗获FDA批准，仅需单针注射</title><link>https://mp.weixin.qq.com/s/iZ5ePtHXjiRyGE_cw3mKzA</link><description></description><content:encoded><![CDATA[强生新冠疫苗获FDA批准，仅需单针注射]]></content:encoded><pubDate>Sun, 28 Feb 2021 09:12:22 +0800</pubDate></item><item><title>国内首个：鲁南制药申报BCMA/CD3双抗</title><link>https://mp.weixin.qq.com/s/USmAQEQtBbk7O6zHR-LrWg</link><description></description><content:encoded><![CDATA[国内首个：鲁南制药申报BCMA/CD3双抗]]></content:encoded><pubDate>Sat, 27 Feb 2021 10:44:13 +0800</pubDate></item><item><title>尚健生物研发BCMA ADC药物</title><link>https://mp.weixin.qq.com/s/M_QUpP9M-pERBJxAlAgsQA</link><description></description><content:encoded><![CDATA[尚健生物研发BCMA ADC药物]]></content:encoded><pubDate>Fri, 26 Feb 2021 07:24:53 +0800</pubDate></item><item><title>熙宁小课 | 基于细胞平台的双特异抗体临床PK检测分析方法</title><link>https://mp.weixin.qq.com/s/JSAhiHF0sRpdJUu04rNbqg</link><description></description><content:encoded><![CDATA[熙宁小课 | 基于细胞平台的双特异抗体临床PK检测分析方法]]></content:encoded><pubDate>Fri, 26 Feb 2021 07:24:53 +0800</pubDate></item><item><title>百济神州2020：PD-1销售额10亿元，研发费用83亿元</title><link>https://mp.weixin.qq.com/s/PeKcvJIHQ22AIPNV6eQxVw</link><description></description><content:encoded><![CDATA[百济神州2020：PD-1销售额10亿元，研发费用83亿元]]></content:encoded><pubDate>Fri, 26 Feb 2021 07:24:53 +0800</pubDate></item><item><title>诺和诺德申报首款双抗：FIX/FX</title><link>https://mp.weixin.qq.com/s/Vat8DGny5DKrjHiQyCapUQ</link><description></description><content:encoded><![CDATA[诺和诺德申报首款双抗：FIX/FX]]></content:encoded><pubDate>Thu, 25 Feb 2021 14:19:33 +0800</pubDate></item><item><title>三生国健申报HER2抗体：靶向HER2 ECD3</title><link>https://mp.weixin.qq.com/s/stUB2XEhTe5UY5epSEjOrA</link><description></description><content:encoded><![CDATA[三生国健申报HER2抗体：靶向HER2 ECD3]]></content:encoded><pubDate>Thu, 25 Feb 2021 14:19:33 +0800</pubDate></item><item><title>百奥泰申报OX40抗体：国内第6家</title><link>https://mp.weixin.qq.com/s/1DbrVhuyb3HUNB89PhNIpA</link><description></description><content:encoded><![CDATA[百奥泰申报OX40抗体：国内第6家]]></content:encoded><pubDate>Thu, 25 Feb 2021 14:19:33 +0800</pubDate></item><item><title>君实生物申报首个双抗：PD-1/TGFβ</title><link>https://mp.weixin.qq.com/s/_nXR2PK_oZwJAowJiLuQhw</link><description></description><content:encoded><![CDATA[君实生物申报首个双抗：PD-1/TGFβ]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:23:03 +0800</pubDate></item><item><title>君实生物申报EGFR-exon20小分子抑制剂</title><link>https://mp.weixin.qq.com/s/pVWzeLDrSn4pgSc3Uhc7mA</link><description></description><content:encoded><![CDATA[君实生物申报EGFR-exon20小分子抑制剂]]></content:encoded><pubDate>Mon, 22 Feb 2021 16:14:15 +0800</pubDate></item><item><title>100款已上市抗体药物氨基酸序列</title><link>https://mp.weixin.qq.com/s/zxl0uNYyOF_qKiG_G3TleA</link><description></description><content:encoded><![CDATA[100款已上市抗体药物氨基酸序列]]></content:encoded><pubDate>Sun, 21 Feb 2021 21:28:19 +0800</pubDate></item><item><title>100款已上市抗体药物的免疫原性</title><link>https://mp.weixin.qq.com/s/fiSEr-INBnvToOsk_Tkw0w</link><description></description><content:encoded><![CDATA[100款已上市抗体药物的免疫原性]]></content:encoded><pubDate>Sun, 21 Feb 2021 21:28:19 +0800</pubDate></item><item><title>100款已上市抗体药物的制剂处方</title><link>https://mp.weixin.qq.com/s/SWb_HKP61b6RZEUQ5V9p_Q</link><description></description><content:encoded><![CDATA[100款已上市抗体药物的制剂处方]]></content:encoded><pubDate>Sun, 21 Feb 2021 21:28:19 +0800</pubDate></item><item><title>VEGF治疗眼病：罗氏的三重护城河</title><link>https://mp.weixin.qq.com/s/zMR7UzBySTYBfCjeE4VVAQ</link><description></description><content:encoded><![CDATA[VEGF治疗眼病：罗氏的三重护城河]]></content:encoded><pubDate>Sat, 20 Feb 2021 14:16:17 +0800</pubDate></item><item><title>多特异性纳米抗体：或成对抗新冠变异的有效武器</title><link>https://mp.weixin.qq.com/s/Osl0PQ2_cGfYcMg1XOJxAw</link><description></description><content:encoded><![CDATA[多特异性纳米抗体：或成对抗新冠变异的有效武器]]></content:encoded><pubDate>Fri, 19 Feb 2021 09:27:29 +0800</pubDate></item><item><title>成立6个月，联拓生物启动FGFR抑制剂三期临床</title><link>https://mp.weixin.qq.com/s/Q2ne2z7Bi8gdtWjs7v74Sg</link><description></description><content:encoded><![CDATA[成立6个月，联拓生物启动FGFR抑制剂三期临床]]></content:encoded><pubDate>Fri, 19 Feb 2021 09:27:29 +0800</pubDate></item><item><title>国内首个：迈威生物申报ST2抗体</title><link>https://mp.weixin.qq.com/s/fddboQe5XXcv0p4qwCDRqw</link><description></description><content:encoded><![CDATA[国内首个：迈威生物申报ST2抗体]]></content:encoded><pubDate>Fri, 19 Feb 2021 09:27:29 +0800</pubDate></item><item><title>David Baker成功实现跨膜TMB的从头设计</title><link>https://mp.weixin.qq.com/s/i3saMA1qCCfPA2u-SswR9A</link><description></description><content:encoded><![CDATA[David Baker成功实现跨膜TMB的从头设计]]></content:encoded><pubDate>Fri, 19 Feb 2021 09:27:29 +0800</pubDate></item><item><title>全人源抗体</title><link>https://mp.weixin.qq.com/s/DXGT00Exm8PNDsfg39pcrg</link><description></description><content:encoded><![CDATA[全人源抗体]]></content:encoded><pubDate>Thu, 18 Feb 2021 09:08:33 +0800</pubDate></item><item><title>豪森药业1.32亿美元引进抗真菌感染药物</title><link>https://mp.weixin.qq.com/s/NHZQyII9835qPZY6HoDQNA</link><description></description><content:encoded><![CDATA[豪森药业1.32亿美元引进抗真菌感染药物]]></content:encoded><pubDate>Thu, 18 Feb 2021 09:08:33 +0800</pubDate></item></channel></rss>